R&D revolution for drugs could secure good, affordable prices
This article was originally published in SRA
Drug companies that want to offer payers a more attractive price to secure market access for their new innovations should try a whole new approach to R&D. Step away from the randomized control trial (RCT), consult with patients and exploit data already out there, says Stuart Dollow, chief executive and founder of Vermilion Life Sciences, and you could potentially afford more flexibility on price.
Register for our free email digests: